Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations

Kevin P. Bliden, Tiancheng Liu, Deepika Sreedhar, Jessica Kost, Jessica Hsiung, Su Zhao, Dingying Shan, Abira Usman, Naval Walia, Alastair Cho, Christophe Jerjian, Udaya S. Tantry, Paul A. Gurbel, Meijie Tang, Hongjie Dai
doi: https://doi.org/10.1101/2021.06.28.21259338
Kevin P. Bliden
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiancheng Liu
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepika Sreedhar
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Kost
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Hsiung
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su Zhao
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dingying Shan
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abira Usman
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naval Walia
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair Cho
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Jerjian
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Udaya S. Tantry
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Gurbel
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD 21215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pgurbel{at}lifebridgehealth.org meijie.tang{at}nirmidas.com hdai{at}stanford.edu
Meijie Tang
2Nirmidas Biotech Inc., Palo Alto, CA 94303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pgurbel{at}lifebridgehealth.org meijie.tang{at}nirmidas.com hdai{at}stanford.edu
Hongjie Dai
3Stanford University, Department of Chemistry and Bio-X, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pgurbel{at}lifebridgehealth.org meijie.tang{at}nirmidas.com hdai{at}stanford.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between vaccines. Here we performed a prospective pilot study of 71 previously COVID-19 free subjects upon receiving both doses of either the Pfizer (n = 54) or Moderna (n = 17) mRNA vaccine. Anti-spike protein receptor binding domain (RBD) IgG antibodies were measured longitudinally using a qualitative finger stick MidaSpot™ rapid test at the point-of-care for initial screening and a quantitative dry blood spot-based pGOLD™ laboratory test over ∼ four months post-vaccination. The average anti-RBD IgG antibody levels peaked at ∼ two weeks after the second dose of the vaccine and declined thereafter, while antibody avidity increased, suggesting antibody maturation. Moderna vaccine recipients compared to Pfizer vaccine recipients exhibited higher side effect severity, higher peak anti-RBD IgG antibody levels, and higher avidity up to the 90 days period. Differences in antibody levels diminished at ∼ 120 days post-vaccination, in line with the similar efficacy observed in the two vaccines. The MidaSpot™ rapid test detected 100% anti-SARS-CoV-2 RBD positivity for fully vaccinated subjects in both Pfizer and Moderna cohorts post full vaccination but turned negative greater than 90 days post-vaccination for 5.4% of subjects in the Pfizer cohort, whose quantitative anti-IgG were near the minimum levels of the group. Immune responses were found to vary greatly among vaccinees. Personalized longitudinal monitoring of antibodies could be necessary to assess the immunity duration of vaccinated individuals.

Competing Interest Statement

Dr. Gurbel reports grants and personal fees from Bayer HealthCare LLC, Otitopic Inc, Amgen, Janssen, and US WorldMeds LLC; grants from Instrumentation Laboratory, Haemonetics, Medicure Inc, Idorsia Pharmaceuticals, and Hikari Dx; personal fees from UpToDate; Dr Gurbel is a relator and expert witness in litigation involving clopidogrel; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients issued and Assessment of cardiac health and thrombotic risk in a patient. Dr. Tantry reports receiving honoraria from UptoDate and Aggredyne. H. Dai worked on this project as a consultant for Nirmidas Biotech Inc., independent of his Stanford projects.

Clinical Trial

NCT04910971

Funding Statement

This work was supported by Nirmidas Biotech. Inc. internal R&D funds and funds from Platelet and Thrombosis Research, LLC, Baltimore, MD, USA

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

LifeBridge Health local institutional review board under Protocol # 1707882

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available in main manuscript and Supplementary information. Further requests for materials should be addressed to P.A.G, M.T. and H.D.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
Kevin P. Bliden, Tiancheng Liu, Deepika Sreedhar, Jessica Kost, Jessica Hsiung, Su Zhao, Dingying Shan, Abira Usman, Naval Walia, Alastair Cho, Christophe Jerjian, Udaya S. Tantry, Paul A. Gurbel, Meijie Tang, Hongjie Dai
medRxiv 2021.06.28.21259338; doi: https://doi.org/10.1101/2021.06.28.21259338
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
Kevin P. Bliden, Tiancheng Liu, Deepika Sreedhar, Jessica Kost, Jessica Hsiung, Su Zhao, Dingying Shan, Abira Usman, Naval Walia, Alastair Cho, Christophe Jerjian, Udaya S. Tantry, Paul A. Gurbel, Meijie Tang, Hongjie Dai
medRxiv 2021.06.28.21259338; doi: https://doi.org/10.1101/2021.06.28.21259338

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13378)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5155)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3271)
  • Health Policy (1141)
  • Health Systems and Quality Improvement (1191)
  • Hematology (431)
  • HIV/AIDS (1018)
  • Infectious Diseases (except HIV/AIDS) (14632)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4927)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (725)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4214)
  • Public and Global Health (7506)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1014)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)